Investor sentiment turns negative as MacroGenics reports trial deaths

Despite a lower dose, data from the Phase II stage of the TAMARACK study have raised concerns over the safety profile of MacroGenics’ (Nasdaq: MGNX) antibody-drug conjugate (ADC), vobra duo.

The company reported five deaths in the trial, with a grade 3 or worse adverse event affecting more than half of patients.

While two of the fatalities were deemed unrelated to the test drug, three deaths in the higher dose arm remain under investigation by trial monitors.